吉西他滨联合替吉奥胶囊治疗晚期胰腺癌的疗效观察

目的探讨吉西他滨联合替吉奥胶囊化疗方案与吉西他滨单药治疗进展期胰腺癌的疗效。方法对2008年1月至2011年1月收治的52例晚期胰腺癌患者的临床资料进行回顾性分析,其中28例采用吉西他滨联合替吉奥胶囊方案治疗(A组);24例采用吉西他滨单药治疗(B组)。采用Kaplan-Meier法分析患者的生存时间,并比较两组患者的客观缓解率、临床受益反应(CBR)、中位疾病进展时间、中位生存时间和不良反应。结果 A组有效率明显高于B组(32.1%vs.20.8%),差异有统计学意义(P=0.039)。A组疾病控制率(DCR)高于B组(67.9%vs.45.8%),但差异无统计学意义(P=0.230)。A组患者CBR缓解率高于B组(72.1%vs.46.9%),差异无统计学意义(P=0.41)。A组的中位生存时间为10.2个月(95%CI:8.0～11.8个月),高于B组的8.03个月(95%CI:3.8～10.9个月),差异有统计学意义(P=0.045);A、B两组的中位疾病进展时间分别为3.6个月和3.0个月(P=0.721)。A组的6个月生存率(72.7%)略高于B组(66.8%),但差异无统计学意义(P>0.05)。两组不良反应的发生率也相似(P>0.05)。结论吉西他滨联合替吉奥胶囊治疗方案与单药治疗晚期胰腺癌相比,在客观疗效、中位生存时间表现出一定优势,疾病控制率及临床受益反应也有所提高,且不良反应可耐受,是晚期胰腺癌的有效治疗方案。

The efficacy of Gemcitabine plus Gimeracil and Oteracil Porassium Capsules chemotherapy on advanced pancreatic cancer

Objective This study was to compare the efficacy of GEM plus gimeracil and oteracil porassium capsules(S-1) and GEM alone on advanced pancreatic cancer.Methods From January 2008 to January 2011,52 patients of advanced pancreatic cancer were analyzed retrospectively.Of 52 APC patients,28 received GEM and S-1(A group),24 received GEM(B group).The survival was analyzed by Kaplan-Meier method.Overall survival rate,clinical benefit response(CBR),Median time to progression(mTTP),median overall survival(mOS) and adverse events were assessed according to World Health Organization criteria.Results The combination group(group A) efficient obviously higher than gemcitabine single drug group(group B)(32.1% vs.20.8%,P=0.039).The disease control rates(DCR) was 67.9% in the group A and 45.8% in the group B,there was no significant difference in the DCR(P=0.230).The CBR was 72.1% in the group A and 46.9% in the group B,there was no significant difference in the CBR(P=0.41).The group A median survival time was 10.2 months(95% CI: 8.0～11.8 months),higher than the group B 8.03 months(95% CI: 3.8～10.9 months),there was significant difference between the two groups in the median survival time(P =0.045);A,B two groups of median time to progression were 3.6 months and 3.0 months(P=0.721).The six months survival rate was 72.7% in the group A and 66.8% in the group B;there was no significant difference in the six months survival rate(P>0.05).There was no significant difference in adverse events between the two groups(P>0.05).Conclusions The combination of gemcitabine and S-1 chemotherapy can increase the survival rate and appears to be a beneficial treatment for patients with advanced pancreatic cancer.